Compare Howmet Aerospace Inc (HWM) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Howmet Aerospace Inc vs Sanofi SA — how do they compare? Howmet Aerospace Inc trades at $225.06 (market cap $88.76B), while Sanofi SA trades at $40.04 (market cap $95.18B). The key difference: Howmet Aerospace Inc and Sanofi SA are close in size by market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Howmet Aerospace Inc for 35 Days and Sanofi SA for 94 Days on average.
| HWM | SNY | |
|---|---|---|
Market Cap | $88.76B | $95.18B |
Volume | 2,648,516 | 2,995,646 |
Sector | Industrials | Health |
52-Week High | $292.65 | $52.34 |
52-Week Low | $184.09 | $39.51 |
Typical Hold Time | 35 Days | 94 Days |
Enterprise Value | $92.86B | $114.48B |
Dividend Yield | 0.25% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Howmet Aerospace (HWM) trades at $225.55, up 1.28% today, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected soon. Revenue and net income are projected to grow in 2026, supported by robust demand in aerospace and defense. Analyst consensus is overwhelmingly bullish, with an 84% buy rating and a $328.10 price target, indicating significant upside potential from current levels.
The outlook for HWM is positive, driven by earnings growth and sector tailwinds, though technical indicators suggest near-term caution. Key risks include supply-chain pressures and competitive dynamics. Institutional interest remains strong, supporting the long-term investment case for shareholders focused on aerospace exposure.
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Howmet Aerospace Inc
Howmet Aerospace provides advanced engineered solutions for the aerospace and transportation industries. It specializes in jet engine components, aerospace fastening systems, and forged aluminum wheels.
Read more on HWM →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
